TP53 and cancer: As a negative regulator of p53, it is notsurprising that MDM2 amplification and/or overexpression arefrequently observed in human cancers, such as many subtypes of sarcomas as wellas gliomas and leukemias (Karni-Schmidtet al., 2016).